Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL772

RESERPINE
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC

Basic Information

ChEMBL ID CHEMBL772
Name RESERPINE
Phase Approved
Structure Type MOL
InChI Key QEVHRUUCFGRFIF-MDEJGZGSSA-N
Therapeutic ✓ Yes

Known Names

Apoplon ENT-50146 Hiserpia NSC-237659 NSC-59272 Rau-sed Reserpina Reserpine Reserpine component of cam-ap-es Reserpine component of demi-regroton Reserpine component of diutensen-r Reserpine component of dralserp +18 more
19
Targets
68
Activities
3
Assay Types
4
PK Parameters
20
Publications
30
Known Names
13
Indications
1
Mechanisms

Molecular Properties

608.7
MW (Da)
4.17
ALogP
10
HBA
1
HBD
117.8
PSA (Ų)
0.37
QED
1
Ro5 Violations
8
Rot. Bonds

Drug Information

Molecule Type Small molecule
First Approval 1960
Availability Withdrawn
Chirality Single Enantiomer

Routes of Administration

Oral Parenteral

Flags

Withdrawn Natural Product
USAN Stem -pine; -serpine

Extended Properties

Molecular Formula C33H40N2O9
MW 608.69
Aromatic Rings 3
Heavy Atoms 44
NP-Likeness 0.93

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Synaptic vesicular amine transporter inhibitor INHIBITOR Synaptic vesicular amine transporter

Indications

Hypertension Atherosclerosis Cardiovascular Diseases Cerebrovascular Disorders Coronary Disease Diabetes Mellitus, Type 2 Heart Diseases Hypercholesterolemia Cocaine-Related Disorders Substance-Related Disorders Vascular Diseases Amphetamine-Related Disorders Hypertension, Pulmonary

ATC Classification

C02AA02
reserpine
Level 1: CARDIOVASCULAR SYSTEM
Level 2: ANTIHYPERTENSIVES
C02AA52
reserpine, combinations
Level 1: CARDIOVASCULAR SYSTEM
Level 2: ANTIHYPERTENSIVES

Drug Warnings

Withdrawn
General Warning
associated with a greater frequency and severity of adverse effects in strengths greater than 1 mg
Country: United States   Year: 1977

Activity Summary

IC50 50 meas. best 8.75
Ki 17 meas. best 9.0
Kd 1 meas. best 8.1

Target Activity Profile

Target Type Best pChEMBL Mean pChEMBL Best (nM) # Data
Synaptic vesicular amine transporter
CHEMBL4271
Ki 9.0 9.0 1.0 1
Synaptic vesicular amine transporter
CHEMBL4295886
IC50 8.75 8.75 1.8 1
Synaptic vesicular amine transporter
CHEMBL1893
Ki 8.28 6.9567 5.3 3
Synaptic vesicular amine transporter
CHEMBL1893
Kd 8.1 8.1 8.0 1
Synaptic vesicular amine transporter
CHEMBL1893
IC50 7.88 7.845 13.2 2
Chromaffin granule amine transporter
CHEMBL1838
IC50 7.3 7.3 50.0 1
ATP-dependent translocase ABCB1
CHEMBL4302
Ki 7.0 5.7 100.0 5
Plasmodium falciparum
CHEMBL364
IC50 6.5 5.8714 316.2 7
ATP-dependent translocase ABCB1
CHEMBL4302
IC50 6.3 5.564 500.0 10
Unchecked
CHEMBL612545
Ki 6.28 5.9025 528.0 4
Unchecked
CHEMBL612545
IC50 6.11 5.51 774.0 6
Sodium channel alpha subunits; brain (Types I, II, III)
CHEMBL2096682
IC50 5.8 5.8 1600.0 1
Mu-type opioid receptor
CHEMBL233
Ki 5.77 5.77 1686.0 1
Acetylcholinesterase
CHEMBL220
IC50 5.77 5.77 1700.0 1
Cholinesterase
CHEMBL1914
IC50 5.55 5.55 2800.0 1
SARS-CoV
CHEMBL4303836
IC50 5.47 5.47 3400.0 1
ATP-dependent translocase ABCB1
CHEMBL2573
Ki 5.39 5.39 4030.0 1
Mu-type opioid receptor
CHEMBL233
IC50 5.38 5.38 4152.0 1
Quinolone resistance protein NorA
CHEMBL5114
IC50 5.16 5.0713 7000.0 8
Bile salt export pump
CHEMBL6020
IC50 5.08 5.0575 8350.0 4
Broad substrate specificity ATP-binding cassette transporter ABCG2
CHEMBL5393
IC50 4.93 4.8033 11800.0 3
ATP-dependent translocase ABCB1
CHEMBL3467
Ki 4.75 4.75 17900.0 1
HL-60
CHEMBL383
IC50 4.17 4.17 67000.0 1
ATP-binding cassette sub-family C member 2
CHEMBL5748
IC50 4.17 4.17 68400.0 1

Pharmacokinetic Data

Parameter Value Units Species
AUC 8.522 ng.hr.mL-1 Homo sapiens
CL 18.3 mL.min-1.g-1 Homo sapiens
Fu 0.95 - Homo sapiens
T1/2 3.0 hr Homo sapiens

Activity Data Samples

Top measurements by pChEMBL value

Target Type Rel. Value Units pChEMBL Assay PubMed
Synaptic vesicular amine transporter Ki = 1.0 nM 9.0 Inhibition of dopamine uptake at VMAT in bovine chromaffin granule ghosts 18220329
Synaptic vesicular amine transporter IC50 = 1.79 nM 8.75 Inhibition of VMAT2 in C57Bl/6J mouse striatal membranes assessed as reduction i... 30240563
Synaptic vesicular amine transporter Ki = 5.26 nM 8.28 Displacement of [3H]reserpine from human VMAT2 expressed in HEK293 cell membrane... 30240563
Synaptic vesicular amine transporter Kd = 8.0 nM 8.1 Binding affinity to human VMAT2 expressed in HEK293 cell membranes by scintillat... 30240563
Synaptic vesicular amine transporter IC50 = 13.2 nM 7.88 Inhibition of human VMAT2 expressed in HEK293 cell membranes assessed as reducti... 30240563
Synaptic vesicular amine transporter IC50 = 15.5 nM 7.81 Substrate uptake and inhibition of the Vesicular Amine Transporter 2 (VMAT2, SLC... -
Chromaffin granule amine transporter IC50 = 50.0 nM 7.3 Substrate uptake and inhibition of the chromaffin granule amine transporter (VAT... -
ATP-dependent translocase ABCB1 Ki = 100.0 nM 7.0 Concentration giving half of the maximal ATPase activity calculated for the high... 12477351
Plasmodium falciparum IC50 = 316.23 nM 6.5 Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR g... 19734910
Synaptic vesicular amine transporter Ki = 410.0 nM 6.39 Displacement of [3H](+)-syn-Ethyl 1-(2-(2,4-Dioxo-1,2-dihydroquinazolin-3(4H)-yl... 30240563
ATP-dependent translocase ABCB1 IC50 = 500.0 nM 6.3 TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells 11716514
Unchecked Ki = 528.0 nM 6.28 DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand:... -
Synaptic vesicular amine transporter Ki = 630.0 nM 6.2 Displacement of [3H]DHTB from human VMAT2 expressed in HEK293 cell membranes inc... 30240563
Unchecked Ki = 706.0 nM 6.15 DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotox... -
Unchecked IC50 = 774.0 nM 6.11 DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotox... -
Plasmodium falciparum IC50 = 794.33 nM 6.1 Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR gr... 19734910
Unchecked IC50 = 821.0 nM 6.09 DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand:... -
ATP-dependent translocase ABCB1 Ki = 970.0 nM 6.01 TP_TRANSPORTER: increase in Vinblastine intracellular accumulation in MDR1-expre... 11961113
Plasmodium falciparum IC50 = 1258.93 nM 5.9 Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR g... 19734910
Sodium channel alpha subunits; brain (Types I, II, III) IC50 = 1600.0 nM 5.8 Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on vol... 2579237

Literature References

PubMed DOI Target Context # Activities
- 10.5281/zenodo.13943903 ADMET 80
17101679 10.1128/aac.01306-05 Staphylococcus aureus 35
17846144 10.1128/aac.00391-07 Unchecked 27
6492071 10.1021/jm00377a006 Rattus norvegicus 14
18362193 10.1128/aac.01644-07 Streptococcus pneumoniae 14
22194678 10.1371/journal.pcbi.1002310 Hepatotoxicity 14
19687245 10.1128/aac.00853-09 Unchecked 12
18362193 10.1128/aac.01644-07 Unchecked 12
15646539 10.1016/s0399-8320(04)95062-2 Unchecked 11
37938154 10.1021/acs.jnatprod.3c00661 20S proteasome 10
30240563 10.1021/acs.jmedchem.8b00542 Synaptic vesicular amine transporter 10
21051535 10.1124/dmd.110.034629 ADMET 9
30067360 10.1021/acs.jmedchem.8b00791 Staphylococcus aureus 8
15646539 10.1016/s0399-8320(04)95062-2 NON-PROTEIN TARGET 8
12235267 10.1124/jpet.102.037549 ATP-dependent translocase ABCB1 8
11716514 10.1006/bbrc.2001.6000 ATP-dependent translocase ABCB1 7
21751791 10.1021/jm200370y Staphylococcus aureus 7
22682300 10.1016/j.bmc.2012.05.025 Quinolone resistance protein NorA 7
19734910 10.1038/nchembio.215 Plasmodium falciparum 7
8984151 10.1021/np960024c Unchecked 7

Data from ChEMBL 36 via Core Engine